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Abstract
Pheochromocytoma (PHEO) and paraganglioma (PGL) are catecholamine-producing
neuroendocrine tumors that arise respectively inside or outside the adrenal medulla. Sev-
eral reports have shown that adrenal glucocorticoids (GC) play an important regulatory
role on the genes encoding the main enzymes involved in catecholamine (CAT) synthesis
i.e. tyrosine hydroxylase (TH), dopamine β-hydroxylase (DBH) and phenylethanolamine N-
methyltransferase (PNMT). To assess the influence of tumor location on CAT metabolism,
66 tissue samples (53 PHEO, 13 PGL) and 73 plasma samples (50 PHEO, 23 PGL) were
studied. Western blot and qPCR were performed for TH, DBH and PNMT expression. We
found a significantly lower intra-tumoral concentration of CAT and metanephrines (MNs)
in PGL along with a downregulation of TH and PNMT at both mRNA and protein level com-
pared with PHEO. However, when PHEO were partitioned into noradrenergic (NorAd) and
mixed tumors based on an intra-tumoral CAT ratio (NE/E >90%), PGL and NorAd PHEO
sustained similar TH, DBH and PNMT gene and protein expression. CAT concentration
and composition were also similar between NorAd PHEO and PGL, excluding the use of
CAT or MNs to discriminate between PGL and PHEO on the basis of biochemical tests.
We observed an increase of TH mRNA concentration without correlation with TH protein
expression in primary cell culture of PHEO and PGL incubated with dexamethasone dur-
ing 24 hours; no changes were monitored for PNMT and DBH at both mRNA and protein
level in PHEO and PGL. Altogether, these results indicate that long term CAT synthesis is
not driven by the close environment where the tumor develops and suggest that GC alone
is not sufficient to regulate CAT synthesis pathway in PHEO/PGL.
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Introduction
Pheochromocytoma (PHEO) and paraganglioma (PGL) are tumors arising from chromaffin
cells that derive from the embryonic neural crest. The majority of PHEO/PGL cases are known
as sporadic tumors while mutations in genes including VHL (von Hippel-Lindau), RET (Multi-
ple Endocrine Neoplasia type 2), NF1 (Neurofibromatosis type 1), SDH (Succinate Dehydroge-
nase subunits A, B, C and D) and cofactor SDHAF2,MAX (MYC associated factor X), HIF2A
(hypoxia-inducible factor 2A), FH (fumarate hydratase) and TMEM127 (transmembrane pro-
tein 127) account for approximately 40% of tumors [1]. PHEO are located within the adrenal
medulla and PGL (also formerly known as extraadrenal pheochromocytoma) are found in the
sympathetic and parasympathetic ganglia [2]. PGL are more likely to develop metastasis with
an incidence rate of approximately 10% of total PHEO/PGL cases. Both types of tumors pro-
duce and usually secrete larger amounts of catecholamine (CAT) than the adrenal medulla,
due to an up-regulation of tyrosine hydroxylase (TH; EC 1.14.16.2) and dopamine β-hydroxy-
lase (DBH, EC 1.14.17.1) the main enzymes responsible for CAT synthesis. In chromaffin cells
and pheochromocytes, norepinephrine (NE) and epinephrine (E) are stored in vesicles where
they sustain a passive leakage into the cytoplasm before being recaptured in the vesicle pool.
Adrenal medulla is by far the most important site of E production in the body since pheny-
lethanolamine N-methyltransferase (PNMT; EC 2.1.1.), the enzyme that transforms NE into E,
is largely restricted to this tissue and absent from sympathetic nerves that only produce NE [3–
5]. PNMT appears to be down regulated in a large number of PHEO, except in E-secreting tu-
mors. While in adrenal medulla approximately 80% of CAT consist of E, in many PHEO, NE
largely prevails over E in terms of production. PNMT downregulation has been attributed to
dysregulation in hormone and transcription factor concentration that include glucocorticoids
(GC) carried from adjacent cortical cells to medulla by the adrenal portal system [6–12].
In the context of the PHEO-exclusion diagnosis tests performed in our laboratory, we have
noticed lower E and metanephrine (MN) plasma concentrations in patients affected by a PGL
compared to PHEO. This prompted us to study the underlying molecular mechanisms re-
sponsible for the decrease of CAT and especially E synthesis in PGL compared to PHEO. CAT
metabolism, TH, DBH and PNMT expression at both mRNA and protein levels were assessed
in both kinds of tumors. Due to high heterogeneity of PHEO regarding CAT production and
metabolism, we further arbitrarily divided PHEO into two subgroups; mixed PHEO (Mix)
and noradrenergic PHEO (NorAd), arbitrarily based on an intratumoral CAT ratio of NE/E
>90% [13].
Material and Methods
Subjects and samples
Fresh tumor specimens were obtained surgically between 2006 and 2014 in 11 different hospi-
tals and clinics in Switzerland, from 63 patients with histologically confirmed PHEO (13 PGL
and 53 PHEO, 2 patients with bilateral adrenalectomy: (P21/P28 and P43/P44) and one patient
with a PHEO and a simultaneous PGL without signs of malignancy (P25 and P26), (Table 1).
The 27 women and 25 men with PHEO had a mean age of 49 ± 16.9 years (range 12 to 78). For
PGL the cohort consisted of 8 women and 5 men, mean age of 40+/-18.3 years (range 13–72).
Blood samples were collected after 15 min of supine rest. Plasma CAT and MNs were measured
in the same patients having a PHEO, except for two patients whose CAT values in plasma were
not available (P14 and P27), and one additional patient affected by a men2a syndrome that un-
derwent double adrenalectomy at the same time (P43). For PGL there were 10 additional plas-
ma values on top of the 13 for which tissue biopsies were available, without corresponding
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Table 1. Patients and tumors characteristics.
Patient
code
Age Gender Localisation Malignancy Diameter
cm
Weigth
g
PGL Genetic Mix-/
NorAd-
tumor
Hypertension NE
nmol/
L
E
nmol/
L
Free
NMN
nmol/
L
Free
MN
nmol/
L
P01 21 F L - 3.5 nd - men2a Mix- - 2.6 0.1 3.1 1.3
P02 62 F L - 4.5 38 - NT Mix- + 135.4 57.5 12.4 13.7
P03 54 F R - 6x6x3 nd - NT NorAd + 7.8 0.3 28.9 0.5
P04 44 M R - 11 122 - Sp* Mix- + 216.9 28.5 23.2 6.4
P05 67 M R - 3.5x3x3.5 nd - NT NorAd + 59.2 2.5 8.0 1.5
P06 68 F L - 16 1070 - Sp** NorAd + 14.0 0.4 65.0 0.4
P07 72 F abd - 8 100 + NT Mix- + 1.2 0.6 3.4 5.1
P08 78 F R - 3.7 nd - Sp** Mix- + 0.8 0.8 0.6 2.3
P09 40 M L - 6x5.8x5.6 nd - NT Mix- + 49.1 5.1 18.4 4.1
P10 58 M L + 10 nd - Sp* NorAd + 102.4 0.4 83.6 0.6
P11 25 M abd - 10x6x3 115 + SDHB NorAd + 48.3 0.0 6.7 0.5
P12 53 M abd - 4.5 20 + Sp* Mix- + 45.8 0.1 3.6 0.1
P13 64 M L - 4 nd - NT Mix- + 5.0 2.6 3.6 4.3
P14 48 F L - 3 16 - NT Mix- + nd nd nd nd
P15 35 M L - 4 47 - Sp* NorAd + 20.1 0.2 7.6 0.2
P16 20 F abd + 7.5 nd + SDHB NorAd + 60.8 0.1 7.2 0.1
P17 20 M L - 2.5 15 - men2a Mix- + 1.5 0.1 0.6 1.0
P18 43 F L - 3 92 - men2a Mix- - 1.4 0.2 2.3 12.8
P19 22 M R - 3x2x2 38 - Sp* NorAd + 12.3 0.4 4.0 0.2
P20 30 F R - 9.5 128 - NF1 NorAd + 63.6 1.2 37.8 2.3
P21 41 F R - 3 20 - men2a Mix- - 4.7 1.4 2.3 4.3
P22 33 M 1 + 7x5x3 nd + Sp1 Mix- + 56.9 0.1 11.4 0.2
P23 44 F L - 14.5 298 - NT NorAd + 24.5 0.2 43.1 0.1
P24 64 F L - 3 nd - NT Mix- - 3.1 0.6 2.8 2.1
P25 19 M L - 2.5 23 - Sp** NorAd - 6.88 0.25 2.1 0.2
P26 19 M abd - 1 nd + Sp** NorAd - 6.9 0.25 2.05 0.2
P27 53 M L - 1.5 32 - NT NorAd + nd nd 1.7 0.1
P28 43 F L - 7 37 - men2a Mix- - 7.0 1.1 2.7 1.9
P29 66 F L - 8x8x7 209 - NT NorAd + 159.0 0.6 87.6 0.7
P30 42 F 2 - 5.5 nd + Sp2 NorAd - 6.7 0.2 3.2 0.2
P31 66 M R - 7 49 - NT Mix- + 3.4 0.5 4.5 1.2
P32 25 M 3 - 6.5x4.5x4.2 nd + NT Mix- nd 2.1 0.1 0.4 0.1
P33 68 F L - 4.5 nd - NT Mix- + 40.1 1.2 12.5 1.4
P34 63 M L - 10 nd - Sp* Mix- + 23.3 4.9 29.1 45.9
P35 50 F 4 - 5.7 nd + Sp Mix- + 19.4 0.2 19.0 0.4
P36 64 F R - 4.5 14 - NT NorAd + 5.6 0.2 9.4 0.3
P37 54 M R - 5.5x5.7 69 - NT NorAd - 14.3 0.3 5.1 0.2
P38 13 M R - nd nd - Sp3 NorAd nd 44.6 0.1 7.3 0.2
P39 12 M L - 3x2.5x1.7 nd - VHL NorAd + 1.9 0.3 4.1 0.2
P40 47 M L - 3 22 - NF1 Mix- - 3.4 0.5 2.6 1.6
P41 42 F L - 4x4x3 nd - NT Mix- + 3.0 0.5 3.7 1.7
P42 51 F 5 + 8x4.5 nd + SDHB Mix- + 14.9 0.4 3.3 0.2
P43 33 M L - 4 nd - men2a Mix- + 3.5 1.3 21.3 12.2
P44 33 M R - 8 nd - men2a Mix- + 3.5 1.3 21.3 12.2
P45 66 F L - 4 nd - NT Mix- + 4.1 0.9 2.7 1.9
(Continued)
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intra-tumoral values (tissue not collected) (Fig 1). All tumors/plasma tested for metabolites/
mRNA or protein quantification were included in the results reported here. Among the 63 pa-
tients; 47 were affected by a sporadic tumor and 16 by genetic associated tumors (6 had muta-
tions on RET gene, 4 on SDHB, 3 on NF1 and 3 on VHL. 18 patients out of 47 sporadic PHEO
cases were investigated for genetic disease and found to be devoid of SDHA, SDHB, SDHC,
SDHD, RET, VHL or MAX mutations (Table 1 and S1 Table). Identified mutations are re-
ported in supporting information (S1 Table). The decision to perform genetic analysis was
based on patient’s age, suspicion of malignancy and germline mutation and consent in all
cases. There is currently no guidelines in Switzerland to perform systematic genetic analysis on
PHEO/PGL. Malignancy was confirmed when metastasis were shown to develop in non-neu-
roendocrine tissue. Point mutations were screened by automated Sanger sequencing and detec-
tion of intragenic deletions/duplication using multiplex ligation-dependent probe
amplification (MLPA) The study was reviewed and approved by the Ethical Committee of the
Clinical Research of the Biology and Medecine Faculty of the University of Lausanne,
Table 1. (Continued)
Patient
code
Age Gender Localisation Malignancy Diameter
cm
Weigth
g
PGL Genetic Mix-/
NorAd-
tumor
Hypertension NE
nmol/
L
E
nmol/
L
Free
NMN
nmol/
L
Free
MN
nmol/
L
P46 72 F L - 3.2 nd - NT NorAd nd 71.9 1.0 16.1 0.8
P47 13 M liver - nd nd + Sp2 NorAd nd 92.0 0.5 10.5 0.3
P48 59 M L - 1.4 nd - NT Mix- + 3.5 0.3 0.5 0.5
P49 57 F cervical + 3x3.5x4 nd + SDHB NorAd + 164.0 0.2 101.0 0.2
P50 72 M L - 4.5x3.8x2.8 58 - NT Mix- + 4.4 3.1 4.3 3.8
P51 68 F L - 3.5x3.3 nd - NT Mix- + 37.2 4.7 11.0 5.5
P52 40 M R - 4x3x3.4 nd - Sp4 Mix- + 3.3 0.4 1.3 3.5
P53 49 F R - 4 nd - NT Mix- + 7.8 9.5 3.2 9.4
P54 33 M R - 5.5x3.3x2.7 49 - Sp* NorAd - 2.6 0.1 6.6 0.2
P55 29 F L - 4.2x3.9x6 nd - NT Mix- - 0.4 2.0 0.4 0.2
P56 52 F R - 2x2.7x2.5 nd - NT NorAd + 7.8 0.0 3.5 0.1
P57 42 M L - 1.7x.1.5x1.3 nd - VHL NorAd - 2.0 0.2 0.8 0.2
P58 70 M R - 4.5x4.5x2.9 nd - Sp* Mix- + 7.0 2.2 4.0 1.6
P59 55 F L - 3.1 nd - Sp5 NorAd + 5.8 0.6 3.1 0.3
P60 52 M R - 4.5x5.5 nd - NF1 NorAd + 28.4 1.6 8.3 1.2
P61 64 M L - 7.5x5.8x5.8 86 - NT Mix- + 3.1 6.1 1.3 14.2
P62 37 M L - 6.1 nd - men2a Mix- + 22.9 4.2 nd nd
P63 27 F L - 9 nd - VHL NorAd - 5.1 0.1 17.1 0.1
P64 36 M R - 2x1.9x1.8 nd - NT NorAd + 7.0 0.7 1.7 0.3
P66 59 M L - 4.6x3.3x3.4 33 - NT Mix- + 3.2 1.9 5.4 5.4
P67 57 F abd - 1.6x.1.9 nd + NT NorAd + 4.6 0.6 2.5 0.3
Localisation: PHEO were found either in the left (L) or right (R) adrenal gland. PGL were excised from the following location: abd: abdominal; 1: paraortal
right; 2: paraortal left; 3: Glomus vagal right; 4: retroperitonal left, paraortal; 5: abdominal, paraortal. NT: non-tested, Sp*: sporadic, RET, SDHB, -D and
VHL negative for mutation
Sp**: RET and SDHB negative. SP1: SDHA, -B, -C, -D, MAX, VHL negative. SP2: SDHB, -D, RET, VHL, Men1 negative, SP3: SDHB, -C, -D, RET,
negative, SP4: VHL negative, SP5: SDHB, -C, -D, Men1, RET negative. For CAT and metabolites in plasma, upper reference limits are (in nmol/l); NE
(norepinephrine): 6.55, E (epinephrine): 1.23, free NMN (normetanephrine): 1.39, free MN (metanephrine): 0.85, P65 was later shown not to be a PHEO
and do not appear in this table
doi:10.1371/journal.pone.0125426.t001
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Lausanne, Switzerland. Protocol number 95/04, “study of the secretion of catecholamine and
metabolites from human adrenal gland and pheochromocytoma". All patients provided their
written consent to participate in this study and the ethic committee approved the consent pro-
cedure. Parents gave the written consent for any minors included in this study.
Quantitative PCR, western blot and antibodies
PHEO/PGL samples were prepared devoid of remaining healthy tissue by the surgeon or the
pathologist. RNA extraction was performed using Trizol (Invitrogen, Luzern, Switzerland),
and cDNA synthesis using the PrimeScript RT reagent Kit (Takara Bio Inc, Japan). Primers
were chosen with the primer designing tool from the National Center for Biotechnology Infor-
mation (NCBI) and described elsewhere [13]. Real time PCR assays were conducted in 384
wells using Sybergreen (Roche, Basel, Switzerland) with an Applied Biosystems 7900HT SDS
(Life technology, Zug, Switzerland). Negative controls were performed on the same amount of
total RNA without adding the reverse transcriptase (NEC, non enzyme control). All assays
were tested on a cDNA dilution serie with efficiency comprised between 0.98 and 1.0. qPCR
parameters were: 95°C 10 min, 40 cycles 95°C 15 sec. 60°C 1 min and melting curves were as
expected in all cases. Normalisation of gene expression was performed on three reference
genes; TBP (tata-box binding protein), Eef1a1 (eukaryotic translation elongation factor 1 alpha
1) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase). Amplification curves and fold
changes were analysed using the REST 2009 software (Qiagen, Hombrechtikon, Switzerland).
For western blot assays, tissues were disrupted using a micro potter in a lysis buffer containing
PBS with 0.5% triton X-100 and protease inhibitor with EDTA (Complete, Roche) to represent
Fig 1. Flowchart of the patients and tumor samples included in the study. For CAT and MNs
quantification in tissue 63 patients were enrolled and 66 tumors were collected (two patients had bilateral
tumors (P21 and P43) and one had both a PHEO and a PGL (P25)*, see also Table 1. Tumors consisted of
53 PHEO and 13 PGL. Quantification of CAT in plasma was performed on 72 patients from 50 PHEO and 23
PGL patients, (including P25 with both a PHEO and a PGL). The plasma CAT analysis was performed on the
same patient recruited for tissue CAT and MNs study with the following exceptions: two plasma were not
available (P14 and P27) and two tumors were bilaterally excised at the same time (P43 and P44), finally, 10
additional plasma from PGL patients were added in the study without tissue sample available. For MNs
quantification in plasma, sample P62 was not available (instead of P27 for CAT). Three tissue samples for
PHEO and two for PGL were stored in perchloric acid, not compatible for mRNA extraction for qPCR
assay**. 15 PHEO tissue sample were no longer available for WB assays***.
doi:10.1371/journal.pone.0125426.g001
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20% w/v. Samples were fractionated by SDS-PAGE under reducing conditions using 12% pre-
cast gels (Bio-Rad, Reinach, Switzerland). Proteins were electroblotted onto nitrocellulose
membrane and probed with antibodies. Immunoreactive bands were revealed by chemilumi-
nescence assay (PerkinElmer, Schwerzenbach, Switzerland) and the signal was processed by a
digital imaging analyzer (ImageQuant LAS-4000, General Electric, Glattbrugg, Switzerland)
and quantified with the corresponding software (multigauge, General Electric). Quantification
values were given as QL (pixel value)—background (BG). Anti-PNMT polyclonal antibody
raised in rabbit (final dilution 1000x) was purchased from Protos (cat. number CA-401, Protos
Biotech Corp. New York, USA), anti-β-actin mouse monoclonal antibody (final dilution
5000x) was from Sigma (AC-15, cat. number A5441, Sigma-Aldrich-Chemie, Buchs, Switzer-
land) and anti-TH polyconal antibody raised in rabbit (final dilution 1000x) from Millipore
(cat. number AB152, Millipore, Zug, Switzerland). Anti-DBH polyconal antibody raised in rab-
bit (final dilution 5000x) was generated against full length recombinant human DBH protein
[14]. Secondary HRP conjugated anti-mouse and anti-rabbit antibodies were from Bio-Rad
(cat. number 170–6516 and 170–6515, respectively and diluted 4000x).
Primary cell culture
Tumors were cut in small pieces and digested with collagenase (1mg/ml) (Sigma) in Dulbecco's
modified Eagle medium (DMEM, Life technology), under agitation at 37°C until complete dis-
solution of tumor pieces. Cells were washed by centrifugation (235g for 2 minutes), suspended
in DMEM supplemented with 10% fetal bovine serum (Life technology) and platted in 24 well
plates with 1μM dexamethasone (Sigma) in DMEM. After 24 hrs incubation in a humidified,
5% CO2 incubator at 37°C, cells were lysed in 200μl lysis buffer.
CAT and MNs extraction and quantification in tissue and plasma
Tumor tissues were disrupted in perchloric acid 0.1M and were sonicated using a Branson
Sonifier 450 (Branson, Danbury, CT, USA) at full power for 30 seconds. CAT (E and NE), were
extracted using activated alumina in 0.5 ml microcentrifuge tubes and quantified by ultraper-
formance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) [15]. Metane-
phrines (MN and NMN) were extracted and quantified as previously published [16]. Values
are expressed in nanomoles of metabolite per gram of tissue or per liter of plasma.
Statistics
Data was studied using Graph Pad prism 6.0. The differences in CAT, MNs and protein con-
centration (in tissue and/or in plasma) between different types of tumors were assessed using
the t-test unpaired and Mann-Whitney nonparametric test. Differences were considered as sig-
nificant when P<0.05. mRNA expression was quantified and statistically explored with the
REST2009 software from Qiagen.
Results
CAT levels in tumor and plasma of PHEO and PGL affected patients
We observed a lower intra-tumoral concentration of both E and NE per gram of tissue in PGL
compared with PHEO (by 25.6 and 4.2 fold respectively, P<0.01 and P = 0.02) (Fig 2A). Lower
CAT concentration in PGL was associated with TH and PNMTmRNA lower abundance; TH
was downregulated by 2.6 fold P = 0.04 and PNMT by 10.5 fold P<0.01 compared with PHEO,
(Fig 3A) mRNA data were confirmed at the protein level with 1.8 fold, P<0.001 and 2.8 fold,
P<0.001, expression decrease, respectively (Fig 3B). However due to the high heterogeneity of
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Fig 2. Quantification of E, NE, MN and NMN in plasma and tumor tissue. (A) Quantification of
epinephrine (E), norepinephrine (NE), total CATs (E+NE) and NE/E ratio from 53 PHEO (filled circles) and 13
PGL (open circles) samples. Results are given in nanomoles per gram of tissue and represented on a
logarithmic scale. Geographic mean and standard deviation for each group are reported in supporting
information (S2 Table). (B) Same as in A, quantification of CAT in plasma for 50 PHEO and 23 PGL. (C)
Quantification of metanephrine (MN), normetanephrine (NMN), sum of metanephrines (MN+NMN) and NMN/
MN ratio from 53 PHEO (filled circles) and 13 PGL (open circles).(D) Same as in C, quantification of
metanephrines in plasma for 51 PHEO and 23 PGL. ***P<0.001, **P<0.01, *P<0.05, ns: not statistically
significant. For CAT and metanephrines in tumor tissue, minimal values were set at 0.1 nmol/g representing
limit of quantification.
doi:10.1371/journal.pone.0125426.g002
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tumors for CAT content and secretion (Fig 2A and 2B), PHEO were further subdivided into
two groups; PHEO were considered as noradrenergic (NorAd PHEO) when the E concentra-
tion in tumor tissue was below 10% of total CAT (NE+E), and tumors with E concentration
above 10% of total CAT were termed as mixed PHEO (Table 1) as previously published [12].
Hence by comparing these three groups, if differences between PHEO and PGL exist, then
PGL group would clearly be different from both PHEO groups (noradrenergic and mixed) re-
garding CAT metabolism.
E concentration and NE/E ratio in tumor tissue were similar between NorAd PHEO
(n = 23) and PGL (n = 13), while PGL had 261 fold less E concentration compared with mixed
PHEO (n = 30) P<0.0001 (Fig 4A). Total CAT concentration was 9.5 fold lower in PGL com-
pared with mixed tumor P<0.001 but not statistically different from NorAd PHEO (Fig 4A). A
similar correlation was recorded in plasma for E concentration (7 fold decreased in PGL com-
pared to mixed PHEO P<0.001, Fig 4B). No significant difference were observed between
PHEO and PGL (Figs 2B and 4B) for NE and sum of CAT (NE+E), due to the fact that neuro-
nal NE production accounts for most of NE circulating levels while most of plasma E arises
from adrenal synthesis.
Fig 3. mRNA and protein quantification of TH, DBH and PNMT in PGL vs. PHEO. (A) Whisker-box plot of
mRNA relative ratio from 11 PGL vs. 50 PHEO (reference). TH: fold change to reference (FC) 0.38, Standard
error (SE) 0.08–1.94, 95% confidence Interval (CI) 0.003–13.37; PNMT: FC 0.095, SE 0.003–2.35, CI
0–74.06, DBH: not statistically significant (ns). Reporter genes included the following: EEFIA1, GAPDH and
TBP. ***P<0.001, **P<0.01, *P<0.05. (B) Quantification of the signal obtained by western blot for 35 PHEO
(filled circles) and 12 PGL (open circles). Results are given as QL (corresponding band pixel values)-BG
(background pixel value), and calculated values were divided by the β-actin signal value and reported on the
y-axis. Geographic mean and standard deviation for each group are reported in supporting information (S3
Table). ***P<0.001, **P<0.01, *P<0.05, ns; not statistically significant.
doi:10.1371/journal.pone.0125426.g003
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Fig 4. Quantification of E, NE, MN and NMN in plasma and tumor tissue of PGL, mixed and NorAd tumors. (A) Quantification of epinephrine (E),
norepinephrine (NE), total CAT (E+NE) and NE/E ratio from 30 mixed PHEO (Mix, open diamonds); 23 noradrenergic PHEO (NorAd, filled diamonds) and 13
Catecholamine Metabolism Regulation in Pheochromocytoma/ Paraganglioma
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Metanephrine concentration in tumor and plasma of PHEO and PGL
affected patients
We then investigated the possible differences regarding CAT metabolism with respective MN
and NMN content in PHEO and PGL for tumor and plasma concentration. In tumor tissue as
well as in plasma, MN content was lower in PGL (by respectively 20, P<0.0001 and 3.3 fold
P = 0.0001) than in PHEO (mixed and NorAd tumors) (Fig 2C and 2D). NMN concentration
was not different between PGL and PHEO due to neuronal NE production and recaptation by
pheochromocytes. When PHEO were partitioned into mixed and NorAd tumors, there was a
much higher tissue concentration of MN in mixed PHEO compared to PGL (148 fold increase,
P<0.0001) and a slight difference when PGL group was compared with NorAd PHEO (approx.
2 fold increase, P = 0.04) (Fig 4C). A significant difference was also observed between these two
types of tumors (PGL and NorAd) for NMN concentration (4 fold difference P = 0.04), while
the sum of metanephrines (MN+NMN) was not different between NorAd PHEO and PGL and
slightly less abundant in PGL compared to mixed PHEO (3.6 fold decrease, P = 0.01) (Fig 4C).
In plasma, metanephrine concentration patterns were similar to those monitored for CAT
plasma concentration (Fig 4D compared with Fig 4B).
From a genetic point of view, among the 13 patients affected by a PGL from our cohort, 4
tumors were the consequence of an SDHB mutation and 5 were not SDHB or VHL related. NE
and E tissue concentration were not statistically different between patients affected by a PGL
with an SDHB mutation and patients with a PGL not arising from an SDHB or VHL mutation.
(S5 Table).
mRNA and protein quantification of TH, DBH and PNMT
In order to explain differences in CAT concentration and composition within the three groups
of tumors, gene expression of TH, DBH and PNMT was assessed by qPCR. TH and PNMT
genes were down regulated in PGL compared with mixed PHEO by 3.5 and 41.7 fold respec-
tively (P = 0.03 and P =<0.001) while no differences were recorded for DBH (Fig 5A) As ob-
served for E and NE concentration in tumor tissue, there was no significant difference between
CAT synthesis genes expression for PGL and NorAd PHEO (Fig 5B). PNMT was also highly
down regulated in NorAd PHEO compared to mixed PHEO (Fig 5C), in accordance with low
E measured compared with mixed tumor (15.4 fold, P<0.001). In contrast with TH expression
in PGL vs. mixed PHEO, TH in NorAd PHEO was not shown to be down-regulated when com-
pared with mixed PHEO (Fig 5A compared with Fig 5C), even though NorAd tumors contain
significantly less total CAT than mixed tumors.
To ensure that mRNA and protein concentration were correlated, TH, DBH and PNMT
protein expression was measured by western blot among the tumor samples of the three
groups. Signal obtained was normalised with β-actin band intensity (Fig 6A). TH and PNMT
protein expression reflected mRNA tumor concentration; both proteins were shown to be less
abundant in PGL compared to mixed PHEO by respectively 2.1 and 4.4 fold (P<0.001 for both
correlation) (Fig 6B). DBH was slightly down-regulated in PGL compared to mixed PHEO by
PGL (open circles) samples. Results are given in nanomoles per gram of tissue and represented on a logarithmic scale. Geographic mean and standard
deviation for each group are reported in supporting information (S4 Table). (B) Same as in A, quantification of CAT in plasma for 28 mixed PHEO, 22 NorAd
PHEO and 23 PGL. (C) Quantification of MN and NMN sum of MNs (MN+NMN) and NMN/MN ratio from 30 mixed PHEO (Mix, open diamonds); 23 NorAd
PHEO (filled diamonds) and 13 PGL (open circles) samples. (D) Same as in C, quantification of MNs in plasma for 28 mixed PHEO, 22 NorAd PHEO and 23
PGL. ***P<0.001, **P<0.01, *P<0.05, ns: not statistically significant. For CAT and MNs in tumor tissue, minimal values were set at 0.1 nmol/g representing
limit of quantification.
doi:10.1371/journal.pone.0125426.g004
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1.8 fold, P = 0.03 contrasting with mRNA concentration that was unchanged (Fig 5). Interest-
ingly, no significant changes were observed at both mRNA and protein level for the three genes
studied between PGL and NorAd PHEO (Figs 5B and 6B). PNMT protein expression was only
detected in one PGL (P07) in accordance with relatively high E tissue levels for this sample (Fig
6A). CAT values for each tumor were reported under respectively TH, DBH and PNMT ex-
pression signal which showed that in most of tumors, low E level corresponds to undetectable
PNMT signal.
PNMT expression and E synthesis: Correlation with mixed and NorAd
PHEO
Hitherto no report has directly shown the correlation between PNMT protein expression and
E concentration in PHEO/PGL tissue, and it remained to be demonstrated in our study that
low PNMT is directly correlated with low E synthesis independently of tumor localisation.
Hence, PNMT expression was assessed at both mRNA and protein levels by qPCR andWB in
the same set of PHEO analysed for protein expression from Fig 6. Results showed an increase
of 59 fold, (P<0.001) for mRNA expression in mixed vs. NorAd tumor (Fig 7A) and protein
expression was 3.6 fold up-regulated in mixed PHEO (Fig 7B). This indeed demonstrates that,
Fig 5. mRNA and protein quantification of TH, DBH and PNMT in PGL vs. mixed and NorAD PHEO. (A) Whisker-box plot of mRNA relative ratio from
PGL (n = 11) vs. mixed PHEO (n = 28) (reference). TH: reaction efficiency (RE) 0.99, fold change to reference (FC) 0.29, Standard error (SE) 0.04–1.65, 95%
confidence Interval (CI) 0.003–48.29; DBH: not statistically significant (ns); PNMT: RE 0.98, FC 0.024, SE 0.001–0.41, CI 0–4.82. Reporter genes included
the following: EEFIA1, RE 0.99; GAPDH, RE 1.04, TBP, RE 0.97. ***P<0.001, **P<0.01, *P<0.05, (B) Ratio from PGL (n = 11) vs. NorAd PHEO (n = 22)
(reference). (C) Ratio from NorAd PHEO (n = 22) vs. mixed PHEO (n = 28) (reference) PNMT: FC 0.07, SE 0.005–0.93, CI 0.001–10.99.
doi:10.1371/journal.pone.0125426.g005
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independently of tumor localisation, low PNMT levels in PGL and PHEO, at both mRNA and
protein levels, account for low E concentration.
Effects of glucocorticoids on TH, DBH and PNMT gene transcription and
protein expression
To assess experimentally the effects of GC on PNMT, TH and DBH gene expression in primary
cell culture, cells from 4 PGL and 9 PHEO (6 mixed and 3 NorAd tumors) were plated in cul-
ture dishes and incubated with or without dexamethasone for 24 hrs. In PGL cells no signifi-
cant effect on PNMTmRNA was detected. DBH and THmRNA were below quantification
limit due to low material amount available after surgical resection and lower qPCR efficiency
for these two genes compared to PNMT (Fig 8A). In PHEO cells dexamethasone induced a 2.8
fold upregulation of TH compared with non dexamethasone-incubated cells at 24 hrs
Fig 6. TH, DBH and PNMT protein expression in tumors. (A) Western blot of sample tissues from NorAd PHEO (A, n = 14), mixed PHEO (B, n = 21) and
PGL (n = 12). Volumes loaded were 10μl of a 20% w/v extract. E and NE values corresponding to the samples analysed by western blot are given in
nanomoles/gram of tissue, lower quantification limit was set at 1nmole/gram. (B) Quantification of the signal obtained by western blot. Results are given as
QL (corresponding band pixel values)-BG (background pixel value), and calculated values are divided by the β-actin signal value and reported on the y-axis.
Geographic mean and standard deviation for each group are reported in supporting information (S6 Table). ***P<0.001, **P<0.01, *P<0.05, ns; not
statistically significant.
doi:10.1371/journal.pone.0125426.g006
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(P = 0.002), no effect was recorded for DBH and PNMT (Fig 8B) and between mixed (n = 6) vs.
noradrenergic PHEO (n = 3) regarding gene transcription for TH, DBH and PNMT after 24
hrs incubation with dexamethasone. To correlate gene with protein expression, TH, DBH and
PNMT protein concentration was revealed from dexamethasone incubated and control cells
after 24hrs incubation. Absence of activation was confirmed for DBH and PNMT in steroids-
incubated cell compared to control cells while TH up-regulation detected for mRNA was not
confirmed at the protein level.
Discussion
By comparing PHEO and PGL CAT content, genes expression and protein concentration we
aimed to differentiate CAT metabolism in tumor cells developing in a GC-rich environment
with tumors that lost anatomical contact with adrenal cortex.
We first observed that PGL produce and secrete lower amounts of CAT and MNs, especially
E and MN than PHEO tumors occurring in the adrenal gland. It is commonly supposed that
low epinephrine and PNMT concentrations may arise from a disruption of cellular communi-
cation between pheochromocytes from PGL and adrenal cortex. Low GC level may not be able
to transactivate a large array of genes that possess GC-binding sites including PNMT [6–12]
and TH [17]. However, when PHEO were divided into two groups, according to tissue CAT
NE/E ratio, a different scenario took shape; PGL and NorAd PHEO featured similar values
without significant differences regarding all aspects studied (tissue and plasma CAT concentra-
tion as well as gene and protein expression involved in CAT synthesis). This demonstrates that
tumor characteristics, at least regarding CAT production, are not driven by the immediate
Fig 7. PNMT expression in NorAd PHEO vs. mixed tumors. (A) Whisker-box plot of PNMTmRNA relative
ratio from NorAd tumors (including PHEO and PGL, n = 29) vs. mixed tumor (PHEO and PGL, n = 32,
reference). Fold change to reference (FC) 0.06, Standard error (SE) 0.003–0.29, 95% confidence Interval
(CI) 0–22.36; Reporter genes included the following: EEFIA1, GAPDH and TBP. (B) Quantification of the
signal obtained by western blot in Fig 6 for PNMT signal in mixed and NorAd tumor (independently of PHEO
or PGL). Results are given as QL (corresponding band pixel values)-BG (background pixel value) and
calculated value is divided by the β-actin signal value and reported on the y-axis. Geo. mean 0.64 vs. 0.18,
standard deviation: 0.7 and 0.14 for respectively mixed and NorAd tumor.
doi:10.1371/journal.pone.0125426.g007
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environment where the tumor develops, minimising the need of high GC gradients coming
from cortical cells. Furthermore, tumor size was not correlated with NorAd, mixed PHEO or
PGL (S7 Table).
Our results suggest that the initial tumor cell generated presents characteristics that will not
change depending on the environment and location of incidence. Steroids or other factors
from adjacent cortical cells may however have an effect on CAT gene activation, since 54% of
PHEO (19/35) show PNMT activation, contrasting with only one PGL tumor (1/12, 8%) where
PNMT is detected (Fig 6A). PNMT expression in PGL has also been reported elsewhere rang-
ing from 1/12 cases [18], similar with our results, to 9/12 cases [19]. We show in this report
that direct contact with cortical cells is in no case sufficient to transactivate target genes since
NorAd PHEO and PGL sustain similar TH, DBH and PNMT activation. Both kinds of tumors
may have common transcriptional dysregulation independently of steroid or cortical factors
activation. In this scenario oncogenesis occurs before differentiation into chromaffin cells as il-
lustrated by PNMT gene regulation; NorAd PHEO and PGL produce similar amounts of
mRNA while NorAd and mixed PHEO, both in contact with the cortex, show a drastic differ-
ence in PNMTmRNA concentration (Fig 5C). In vivo PNMT activation requires the addition
of several factors, as recently reviewed by Kvetnansky and colleagues [20]. However, GC recep-
tors and transcription factors including Early growth response protein 1 (Egr-1), Specificity
protein 1 (Sp1) and Myc-associated zinc finger protein (MAZ) known to activate PNMT were
shown not to be differentially expressed between adrenergic (Men2a) versus non adrenergic
(VHL) tumors [21]. Hypermethylation of PNMT has been recently demonstrated in SDH and
Fig 8. Dexamethasone effects on primary tumor cells. (A) Whisker-box plot of PNMTmRNA relative ratio from PGL cells (tumors P16, P30, P35 and P42)
incubated with vs. without dexamethasone 1μM for 24 hrs (reference). Reporter genes included the following: EEFIA1, GAPDH and TBP, ns; not statistically
different. (B) Whisker-box plot of TH, DBH and PNMTmRNA relative ratio from PHEO cells (tumors P23, P36, P44, P45, P52, P53, P56, P61 and P62)
incubated with vs. without dexamethasone 1μM for 24 hrs (reference). TH: FC 2.8, SE 1.28–7.55, CI 0.68–17.38, reporter genes included the following:
EEFIA1, GAPDH and TBP. ** P<0.01. (C) Western blot of PHEO cell incubated with (+) or without (-) dexamethasone (Dexa.) 1μM for 24 hrs.
doi:10.1371/journal.pone.0125426.g008
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VHL-related tumors that led to a downregulation of mRNA synthesis [22, 23]. We confirmed
at the protein level the epigenetic silencing of PNMT (all tested tissue samples from SDHB-
and VHL- associated tumors had undetectable PNMT level, Table 1 and Fig 6A), suggesting
that hypermethylation may also explain lack of PNMT protein expression in noradrenergic
PHEO independently of identified mutation
Our results demonstrate that neither in vivo (direct contact between pheochromocytes and
cortical cells) nor in vitro (pheochromocytes treated with dexamethasone) is sufficient to en-
sure PNMT transcription. This contrasts with chromaffin cells from mice and bovines where
treatment with 100nM to 20 μM of dexamethasone results in high PNMT transactivation levels
[24, 25]. We report here an upregulation of TH transcription level following dexamethasone
incubation without effect on final protein concentration.
Pheochromocytoma crisis (PC) induced by GC is a major concern in PHEO-suspected pa-
tients: several PC cases have been reported following corticosteroid administration [26–28], on
the other hand, GC administration in patient without PHEO was not correlated with changes
in plasma CAT and MNs [29]. We demonstrate in the present study that primary PHEO cells
in culture incubated with 1μM of dexamethasone during 24 hrs did not result in a higher pro-
duction of the main enzymes involved in CAT metabolism, suggesting that GC has no direct
impact on long term regulation of catecholamine synthesis in PHEO. The lag phase (5–36 h)
recorded in the majority of reported cases of PC argues against a direct effect on CAT release
as discussed by Druce and colleagues [29] and could have suggested a genetic regulation by ex-
ogenous GC, but we show in this report that it is unlikely. PC is therefore probably due to
other factors (drugs therapy and interaction, trauma surgery) rather than GC treatment [29].
Another aspect of our work was to potentially differentiate between PHEO and PGL by
comparing CAT and MN plasma levels of affected patients. This issue is of great interest for en-
docrinologists receiving positive results from blood tests, providing an initial idea about possi-
ble tumor location before imaging examination. In a previous report Eisenhofer and colleagues
showed that a high concentration of plasma free metanephrine relative to normetanephrine in-
dicates an adrenal location [30]. We also observed a similar correlation (Fig 2D, right panel)
but when PHEO were partitioned as mixed and noradrenergic tumor and compared to PGL,
no differences were detected between noradrenergic PHEO and PGL (Fig 4D right panel).
Hence, no correlations were found that could biochemically differentiate PGL from noradren-
ergic PHEO, giving another piece of evidence that tumor environment may only play a minor
role in PHEO/PGL CAT metabolism.
In conclusion, a specific biochemical phenotype is not determined by the tumor location
and the postulated effect of a strong GC gradient on CAT synthesis and more specifically on E
production is not supported by our work.
Supporting Information
S1 Table. Mutations identified in PHEO/PGL patients from Table 1.Neg: no mutation iden-
tified for the gene considered, NT: gene not screened. : family and/or clinical history of muta-
tion for the gene considered, no additional tests conducted. : mutation on VHL gene
identified in Paris in 1999.
(TIF)
S2 Table. For Fig 2.Quantification of catecholamine and metanephrines in PHEO and PGL
tissue and plasma. Geographic mean and standard deviation for the values reported.
(TIF)
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S3 Table. For Fig 3.Quantification of TH, DBH and PNMT expression in PHEO and PGL tis-
sue and plasma. Geographic mean and standard deviation for the values reported.
(TIF)
S4 Table. For Fig 4.Quantification of catecholamine and metanephrines in mix-, NorAd-
PHEO and PGL in tissue and plasma. Geographic mean and standard deviation for the
values reported.
(TIF)
S5 Table. Plasma and tissue concentration of CAT and MNs from PGL unrelated to SDHB/
VHL mutation and SDHB PGL.
(TIF)
S6 Table. For Fig 6B.Quantification of TH, DBH and PNMT expression in mix-, NorAd-
PHEO and PGL tissue. Geographic mean and standard deviation for the values reported.
(TIF)
S7 Table. Tumor size of mixed PHEO, NorAd PHEO and PGL. Values were taken from
Table 1. When more than one dimension was available, mean value was calculated and re-
ported. No significant differences were observed between the three groups.
(TIF)
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